457
Participants
Start Date
July 27, 2020
Primary Completion Date
March 18, 2022
Study Completion Date
March 18, 2022
GSK3228836
GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.
Placebo
Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.
Nucleos(t)ide therapy
Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.
GSK Investigational Site, Changhua
GSK Investigational Site, Kwaguqa Emalahleni
GSK Investigational Site, Quezon City
GSK Investigational Site, Makati City
GSK Investigational Site, Sofia
GSK Investigational Site, Sofia
GSK Investigational Site, Vosloorus Ext 2
GSK Investigational Site, Sofia
GSK Investigational Site, Lenasia Johannesburg
GSK Investigational Site, Ennerdale
GSK Investigational Site, Durban
GSK Investigational Site, Port Elizabeth
GSK Investigational Site, Sliven
GSK Investigational Site, Songkhla
GSK Investigational Site, New York
GSK Investigational Site, Bangkok
GSK Investigational Site, Bangkok
GSK Investigational Site, Berlin
GSK Investigational Site, Pittsburgh
GSK Investigational Site, Gyeonggi-do
GSK Investigational Site, Milan
GSK Investigational Site, Milan
GSK Investigational Site, Hamburg
GSK Investigational Site, Milan
GSK Investigational Site, Incheon
GSK Investigational Site, Richmond
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Majadahonda (Madrid)
GSK Investigational Site, Málaga
GSK Investigational Site, Decatur
GSK Investigational Site, Miami
GSK Investigational Site, Miami
GSK Investigational Site, Santander
GSK Investigational Site, Taichung
GSK Investigational Site, Seville
GSK Investigational Site, Modena
GSK Investigational Site, Daegu
GSK Investigational Site, Ulsan
GSK Investigational Site, Busan
GSK Investigational Site, Busan
GSK Investigational Site, Chiang Mai
GSK Investigational Site, Kuala Lumpur
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Frankfurt am Main
GSK Investigational Site, Phitsanulok
GSK Investigational Site, Strasbourg
GSK Investigational Site, Lyon
GSK Investigational Site, Limoges
GSK Investigational Site, Los Angeles
GSK Investigational Site, Erlangen
GSK Investigational Site, Clichy
GSK Investigational Site, Créteil
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Shenyang
GSK Investigational Site, Singapore
GSK Investigational Site, Moscow
GSK Investigational Site, Moscow
GSK Investigational Site, Singapore
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Saint Petersburg
GSK Investigational Site, Shanghai
GSK Investigational Site, Craiova
GSK Investigational Site, Kaliningrad
GSK Investigational Site, Timișoara
GSK Investigational Site, Krasnodar
GSK Investigational Site, Chongqing
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Cluj-Napoca
GSK Investigational Site, Wuhan
GSK Investigational Site, Samara
GSK Investigational Site, Chelyabinsk
GSK Investigational Site, Brasov
GSK Investigational Site, Guangzhou
GSK Investigational Site, Singapore
GSK Investigational Site, Novosibirsk
GSK Investigational Site, Novosibirsk
GSK Investigational Site, Красноярск
GSK Investigational Site, Iași
GSK Investigational Site, Galati
GSK Investigational Site, Boston
GSK Investigational Site, Ciudad Autonoma de Buenos Aires
GSK Investigational Site, Buenos Aires
GSK Investigational Site, Calgary
GSK Investigational Site, Victoria
GSK Investigational Site, London
GSK Investigational Site, Toronto
GSK Investigational Site, Montreal
GSK Investigational Site, Regina
GSK Investigational Site, Québec
GSK Investigational Site, Nice
GSK Investigational Site, Pokfulam
GSK Investigational Site, Ehime
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hiroshima
GSK Investigational Site, Hokkaido
GSK Investigational Site, Ishikawa
GSK Investigational Site, Ishikawa
GSK Investigational Site, Kagawa
GSK Investigational Site, Kumamoto
GSK Investigational Site, Kumamoto
GSK Investigational Site, Miyagi
GSK Investigational Site, Nagasaki
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Tokyo
GSK Investigational Site, Lublin
GSK Investigational Site, Mysłowice
GSK Investigational Site, Warsaw
GSK Investigational Site, Łańcut
GSK Investigational Site, Bucharest
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Seoul
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
GSK Investigational Site, London
GSK Investigational Site, Newcastle upon Tyne
GSK Investigational Site, Plymouth
Lead Sponsor
GlaxoSmithKline
INDUSTRY